Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoproteasome subunit beta type-8 (LMP7) is a catalytic subunit of the immunoproteasome, a specialized form of the proteasome complex. It plays a central role in protein degradation, antigen processing for MHC class I presentation, and regulation of immune responses. LMP7 exhibits chymotrypsin-like activity and is upregulated by interferon-gamma (IFNγ). Selective inhibitors targeting LMP7 are being explored therapeutically in autoimmune diseases. Deficiency/mutations are linked with autoinflammatory syndromes.
Selective inhibition of LMP7
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoproteasome subunit beta type-8 (LMP7).